glp-1 neuroinflammation Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders Beyond diabetes and obesity: GLP‐1

In real time, we are witnessing the rise of new obesity therapies that have the potential to dramatically change outcomes at scale

Cell Metab 3(3):153165 Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T et al (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

The CDKN2A locus encodes two distinct tumor suppressors, p16 INK4A and p14 ARF

Liposomes have shown potential in improving the therapeutic outcomes of topically administered drugs for conditions such as psoriasis [12], while related systems like niosomes have demonstrated efficacy in treating psoriasis and hyperpigmentation [13, 14]

10.1371/journal.pone.0231883 36 WuT.ZhangY.ShiY.YuK.ZhaoM.LiuS.et al (2022)

Thumbs up to Zealthy